# Lung Cancer Aspirin is biologically relevant in **lung cancer** for three main reasons. The first is **long-term prevention** in high-risk populations. The second is **anti-metastatic platelet biology**, especially through **TXA2** signalling and circulating tumour-cell survival. The third is possible **chemotherapy sensitisation**, especially in **cisplatin-resistant non-small cell lung cancer**. There is still no **Phase 3 adjuvant aspirin trial** in lung cancer. That means the evidence base is mostly **observational** plus **mechanistic**. Even so, the signal is consistent enough to take seriously. [Read the review](https://pmc.ncbi.nlm.nih.gov/articles/PMC12897594/) ### Overview Lung cancer remains the leading cause of cancer death worldwide. **Non-small cell lung cancer** makes up about **85%** of cases. This cancer also has some of the most active **platelet–tumour** biology of any solid tumour. That matters because circulating lung-cancer cells often rely on platelet cloaking to survive in the bloodstream and seed distant sites. This makes aspirin's **TXA2** and anti-platelet effects especially relevant here. At the same time, non-small cell lung cancer often carries pathway changes in **PIK3CA**, **KRAS**, and **EGFR** that overlap with aspirin-sensitive biology. [Read the study](https://www.nature.com/articles/s41598-019-53134-0) {% hint style="warning" %} The most important lung-cancer-specific caution is not bleeding alone. It is **aspirin hypersensitivity in people with asthma, nasal polyps, or reactive airways**. That question needs to be screened before aspirin is discussed in this setting. {% endhint %} ### Key human data #### Long-term prevention One of the strongest recent population findings comes from the **2025 Danish registry cohort**. Among **538,147** low-dose aspirin users followed for more than 10 years, lung-cancer risk was reduced by **44%** compared with non-users, with a subdistribution hazard ratio of **0.56**. [Read the PubMed record](https://pubmed.ncbi.nlm.nih.gov/39825684/) That reduction was **not** seen with shorter use. The signal only emerged with more than **10 years** of consistent low-dose aspirin exposure. That suggests any lung-cancer prevention effect is a long-term biological shift, not a short-course intervention. Other long-term population datasets also support lower lung-cancer incidence in regular aspirin users, often in the range of about **20% to 40%**, with stronger effects in current or former smokers. [Read the review](https://pmc.ncbi.nlm.nih.gov/articles/PMC9470249/) That fits the epidemiology. Smokers and former smokers sit in the highest-risk group, so that is where a long-term preventive signal would matter most. #### Post-diagnosis and survival Human post-diagnosis data is much thinner than the prevention literature. Still, one retrospective cohort in **inoperable non-small cell lung cancer** reported significantly improved overall survival in aspirin users compared with non-users. [Read the report](https://www.jons-online.com/lung-cancer-monthly-minutes/aspirin-use-improves-survival-in-patients-with-inoperable-non-small-cell-lung-cancer) That does not establish causation. But it is one of the more relevant human datasets because it looks specifically at lung cancer after diagnosis rather than prevention before diagnosis. Broader observational meta-analyses across cancer types also suggest better survival and less metastatic spread with aspirin use, and lung cancer is usually part of that pattern. [Read the overview](https://www.pharmacytimes.com/view/aspirin-s-evolving-role-in-cancer-prevention-and-outcomes) #### The ASPREE caution The **ASPREE** and **ASPREE-XT** studies need to be interpreted carefully. In generally healthy older adults with a median age of **74**, aspirin did **not** reduce overall cancer incidence and was associated with higher cancer mortality at about five years. [Read the summary](https://www1.racgp.org.au/newsgp/clinical/aspirin-ineffective-in-cutting-cancer-risk-in-olde) This is not usually interpreted to mean aspirin causes cancer. The more plausible reading is that **age**, **population selection**, and **timing** matter a great deal. Late-life aspirin exposure in an unselected older population is not the same question as long-term low-dose use in a high-risk population, or aspirin use in a biologically selected cancer setting. ### Mechanistic relevance #### TXA2 and platelet-supported metastasis This is probably the strongest lung-cancer aspirin mechanism. **TXA2 synthase** is expressed in lung tumour-associated endothelial cells, and **TXA2** supports angiogenesis through **VEGF**, **EGFR**, **Src**, and **ERK** signalling. [Read the mechanism study](https://www.nature.com/articles/s41598-019-53134-0) The 2025 **Nature** study made this more clinically interesting. It showed that platelet-derived **TXA2** suppresses **CD8-positive T-cell** killing through an **ARHGEF1 → RhoA** pathway, and lung metastasis was one of the main experimental systems used to validate that effect. [Read the Nature paper](https://www.nature.com/articles/s41586-025-08626-7) In that work: * platelet-derived **TXA2** blocked effective T-cell attack on circulating tumour cells * aspirin restored T-cell activity in tumour-bearing lungs * giving back a **TXA2 analog** reversed aspirin's anti-metastatic effect That is strong mechanistic evidence that the **COX-1 → TXA2 → ARHGEF1** axis matters in lung metastatic biology. [Read a clinical summary](https://conexiant.com/internal-medicine/articles/early-research-finds-aspirin-may-block-cancer-spread-by-boosting-immune-response/) For the broader mechanism page, see [Aspirin and Thromboxane A2 (TXA2)](/myhealingcommunity-docs/off-label-drugs-for-cancer/aspirin-in-oncology/anticancer-mechanisms/aspirin-and-thromboxane-a2-txa2.md). #### Cisplatin sensitisation Lung cancer also has an important second aspirin mechanism. It may help reverse **cisplatin resistance** in resistant **non-small cell lung cancer stem-cell** models. In a 2019 study, cisplatin-resistant stem-like lung-cancer cells showed hyperactivation of the **mTOR**, **Akt**, and **PI3K** axis. Aspirin pre-treatment suppressed **mTOR** transcription, reduced **Akt** activation, reactivated **GSK3β**, and restored cisplatin sensitivity. [Read the study](https://www.nature.com/articles/s41598-019-53134-0) That matters because it appears to be at least partly **COX-independent**. In other words, aspirin may have lung-cancer relevance even when classic **COX-2** signalling is not the dominant driver. This is still **preclinical**. But it is one of the more credible combination-use signals in this cancer type. #### COX-2 and inflammatory pressure The older inflammation story still matters. **COX-2** is overexpressed in many non-small cell lung cancers and often tracks with worse prognosis. Aspirin can reduce **PGE2-driven** proliferation, immune escape, and angiogenic signalling in lung-cancer models. [Read the review](https://pmc.ncbi.nlm.nih.gov/articles/PMC9470249/) This mechanism is less specific than the **TXA2** story. But it supports the broader biological rationale. ### Aspirin-exacerbated respiratory disease This is the most important safety issue that is specific to lung cancer. Around **10% to 20%** of adults with asthma, and a higher proportion of people with nasal polyps, may have **aspirin-exacerbated respiratory disease**. [Read the review](https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2025.1513318/full) This is a hypersensitivity reaction to aspirin and other **non-steroidal anti-inflammatory drugs**. It can cause: * bronchospasm * nasal and sinus symptoms * respiratory compromise in severe cases This matters even more in lung-cancer patients because many already have: * **chronic obstructive pulmonary disease** * asthma * reduced lung reserve * prior thoracic radiation or lung surgery {% hint style="warning" %} Before any aspirin discussion in lung cancer, ask first about: * prior aspirin or NSAID reactions * asthma history * nasal polyps * chronic sinus disease If any of those are present, respiratory review matters before any trial of aspirin use. {% endhint %} ### Clinical positioning | Setting | Evidence | Position | | -------------------------------------------------- | ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- | ------------------------------------------ | | **Long-term prevention with low-dose aspirin** | Strong epidemiological signal after more than 10 years of use, including a **44%** lower lung-cancer risk in a large population study. [Read the PubMed record](https://pubmed.ncbi.nlm.nih.gov/39825684/) | Supportive, but still investigational | | **Post-diagnosis non-small cell lung cancer** | Retrospective cohort suggests improved overall survival in inoperable disease. [Read the report](https://www.jons-online.com/lung-cancer-monthly-minutes/aspirin-use-improves-survival-in-patients-with-inoperable-non-small-cell-lung-cancer) | Supportive, but no randomised confirmation | | **Lung metastasis suppression** | Strong mechanistic validation in lung models through the **TXA2–ARHGEF1** immune-suppression axis. [Read the Nature paper](https://www.nature.com/articles/s41586-025-08626-7) | Strong biological rationale | | **Cisplatin-resistant non-small cell lung cancer** | Preclinical re-sensitisation via **mTOR** and **Akt** signalling. [Read the study](https://www.nature.com/articles/s41598-019-53134-0) | Investigational combination strategy | | **Adjuvant use after surgery** | No lung-cancer randomised trial exists | Not supported yet | | **People with asthma or aspirin hypersensitivity** | Respiratory safety concern may override theoretical benefit. [Read the review](https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2025.1513318/full) | Needs respiratory review first | ### Practical interpretation The lung-cancer aspirin literature is more convincing on **biology** than on definitive clinical proof. The best-supported themes are: * very long-term prevention in higher-risk populations * platelet and **TXA2** suppression during metastasis * possible re-sensitisation of cisplatin-resistant non-small cell lung cancer For many readers, the most useful questions for the care team are: 1. Do I have any history of **aspirin sensitivity**, **asthma**, or **nasal polyps**? 2. What is my lung-cancer subtype, and are **PIK3CA**, **EGFR**, or related pathways part of the biology? 3. Am I receiving **cisplatin-based chemotherapy**, and is resistance suspected? 4. Do my platelets, clotting history, or metastatic pattern suggest active platelet-supported disease biology? The current evidence does **not** put lung cancer in the same category as biomarker-selected colorectal cancer. But the **TXA2** and metastasis story is among the strongest aspirin mechanisms in any non-gastrointestinal tumour type. ### References * Danish registry cohort, 2025 — more than 10 years of low-dose aspirin use and lower lung-cancer risk. [Read the PubMed record](https://pubmed.ncbi.nlm.nih.gov/39825684/) * Yang et al., *Nature* 2025 — **TXA2**, **ARHGEF1**, and anti-metastatic immune restoration in lung metastasis models. [Read the Nature paper](https://www.nature.com/articles/s41586-025-08626-7) * Clinical summary of the anti-metastatic **TXA2** mechanism. [Read the summary](https://hospitalhealthcare.com/clinical/oncology/more-effective-immunotherapies-possible-as-aspirins-anti-metastatic-mechanism-discovered/) * 2019 *Scientific Reports* paper — aspirin re-sensitises cisplatin-resistant non-small cell lung cancer stem cells through **mTOR** and **Akt** effects. [Read the study](https://www.nature.com/articles/s41598-019-53134-0) * Retrospective cohort in inoperable non-small cell lung cancer. [Read the report](https://www.jons-online.com/lung-cancer-monthly-minutes/aspirin-use-improves-survival-in-patients-with-inoperable-non-small-cell-lung-cancer) * Broader review of aspirin mechanisms and clinical outcomes in cancer. [Read the review](https://pmc.ncbi.nlm.nih.gov/articles/PMC9470249/) * ASPREE and older-adult caution summary. [Read the summary](https://www1.racgp.org.au/newsgp/clinical/aspirin-ineffective-in-cutting-cancer-risk-in-olde) * Review of aspirin-exacerbated respiratory disease and respiratory safety context. [Read the review](https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2025.1513318/full) * Systematic review of aspirin's anti-metastatic role. [Read the review](https://pmc.ncbi.nlm.nih.gov/articles/PMC12897594/)

Would you like to ask Abbey about the information shared on this page? Would you like to contribute your experience, research or ideas to this page? Perhaps you want to point out something that needs changing?

Feedback Form

{% hint style="warning" %} This information is for education only. It is not medical advice, diagnosis, or treatment. Please speak with a qualified clinician before making changes to care, medication, or supplement use. {% endhint %} {% hint style="info" %} © 2026 Abbey Mitchell. All rights reserved. Please share by URL rather than copying page text. {% endhint %} --- # Agent Instructions: Querying This Documentation If you need additional information that is not directly available in this page, you can query the documentation dynamically by asking a question. Perform an HTTP GET request on the current page URL with the `ask` query parameter: ``` GET https://myhealingcommunity.gitbook.io/myhealingcommunity-docs/off-label-drugs-for-cancer/aspirin-in-oncology/aspirin-evidence-by-cancer-type/lung-cancer.md?ask= ``` The question should be specific, self-contained, and written in natural language. The response will contain a direct answer to the question and relevant excerpts and sources from the documentation. Use this mechanism when the answer is not explicitly present in the current page, you need clarification or additional context, or you want to retrieve related documentation sections.